BioNTech, DualityBio weigh future of HER2 ADC after modest Phase 3 breast cancer results
read at Endpoints ↗Positive readoutNeutral
BioNTech and DualityBio are assessing next steps for their HER2-targeted antibody-drug conjugate trastuzumab pamirtecan after a Phase 3 trial in breast cancer.
The trial met its primary endpoint, showing a statistically significant improvement versus control, but the magnitude of benefit was described as modest.
The companies have not announced further development plans, but they are considering options such as additional studies, regulatory discussions, or potential combination strategies.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer results”
read at Endpoints ↗86 words · retrieved 23m ago
comments(0)
5-min edit window · permanent after that